Essential reading for the healthcare business
 
 
Remember me:
Skip Navigation LinksHealthInvestor article
A sting in the tail

Does CVS Group’s share price fall indicate the vets space has lost its shine, asks Ploy Radford

Most people on the planet are mad about animals. Social media users go wild over a cute puppy picture, and investors start salivating over a growing veterinary clinic platform. Or at least they have done, but could things be about to change?

The rising number of companion animals being bred and acquired, the human inability to say no to paying for the best care for their beloved pet, a changing vet workforce that wants to be salaried within a corporate organisation, and advances in animal care techniques have all contributed to the boom in investors hunting down a veterinary clinic platform. Independent Vetcare, for instance, was acquired by EQT last year for a staggering 19x ebitda, if reports are to be believed.  

But the fall in CVS Group’s share price following its latest round of results indicates that things are not looking so cute in the veterinary space. Speaking at the London-listed veterinary services provider’s AGM on the 30 November, chairman Richard Connell admitted that excluding the sales of its Animed Direct division (which sells animal medicines), like-for-like sales were up by just 1.5%. The board of CVS attributed the slowing in growth to the “greater general uncertainty widely evident in the UK economy and some shortage of clinicians in the UK”, with the latter exacerbated by the vote to leave the European Union, it said.

In other words, there actually is a limit to what people will pay for their pooches when economic headwinds are bitter, and there’s no point growing your number of assets if you can’t staff them – and there is a serious staffing problem in the UK.

As a result of Connell’s words, share price at the firm plummeted by 28.1% to 1,010 pence by the end of the day.

Connell said it intends to raise salaries by more than inflation as well as provide more flexible working arrangements to attract more veterinary surgeons and nurses. The salary increases will be funded through price increases, he added. No doubt, because like most veterinary consolidators they have splurged a lot of money on acquisitions (buying 21 new surgeries since the 1 July 2017 alone), as sellers can command punchy prices, they now can’t fund pay rises from their own reserves.

However, given that economic uncertainty has also put customers off, it is a little hard to see how raising prices will help. CVS might as well copy one of its canine customers and start chasing its own tail.

Investors who think the veterinary space promises an easy return would do well to rein in their acquisitive desires and keep a close eye on CVS’s share price.    

 

Posted on: 01/12/2017

Latest news stories

25/09/2018
NHS England’s national director of transforming health systems Michael Macdonnell will leave to join Google Deepmind Health next year.
25/09/2018
Ignite Growth today announced the acquisition of Cornerstone Healthcare Group, a specialist care home operator in the Southeast.
25/09/2018
Ingenica Solutions has raised £4 million in a Series A funding, following an initial investment round.
25/09/2018
The government is considering launching a new ‘care ISA’ to incentivise the public to pay towards their own long-term social care.
24/09/2018
Nearly one in three knee replacements and 20% of hip replacements that are NHS funded are carried out by private healthcare providers, according to latest figures


Civica


HealthInvestor blog
A long-awaited funding settlement for the NHS, a new health secretary, and further delay for the green paper – plus ça change, reflects deputy editor Sarah Williams.

Click here to view the HealthInvestor blog


Regulatory director, ex ‘tea girl’, and devoted new grandparent
Inmates of the UK’s prison service face a double bind of rising health issues and a growing shortage of medical staff, find Clare Connell and Ryan Perrott of Connell Consulting
As each month that passes brings a new chapter to the sleep-ins debate, HealthInvestor UK casts its eye over the history of the issue, and asks sector experts what the eventual outcome might be
Following the launch of a new medically-focused dermatology platform in July, Ross Davies asks if consolidators in this untapped UK market can look to replicate the returns seen in the likes of dental and veterinary
The arrival of infrastructure funds in the healthcare sector may herald longer hold periods for many investments – but are there enough quality assets in the market to justify long-term plays, asks Rod James

Click here to search all feature articles



M&A

The arrival of infrastructure funds in the healthcare sector may herald longer hold periods for many investments - but are there enough quality assets in the market to justify long-term plays, asks Rod James
Read more


Christie + Co

my images



interview: Daya Thayan

Co-founder and chief executive of Kingsley Healthcare Daya Thayan is taking a family approach to growing the business. Sarah Williams travels to the head offices in Lowestoft to find out more
Read more